Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $51.00.
SRRA has been the subject of a number of analyst reports. Lifesci Capital downgraded shares of Sierra Oncology from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 13th. Oppenheimer downgraded shares of Sierra Oncology from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $45.00 to $55.00 in a report on Thursday, April 14th. Jefferies Financial Group downgraded shares of Sierra Oncology from a “buy” rating to a “hold” rating and lifted their target price for the stock from $39.00 to $55.00 in a report on Thursday, April 14th. Zacks Investment Research raised shares of Sierra Oncology from a “sell” rating to a “hold” rating in a report on Saturday, January 22nd. Finally, HC Wainwright downgraded shares of Sierra Oncology from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $51.00 to $55.00 in a report on Wednesday, April 13th.
In related news, insider William D. Turner sold 3,453 shares of the company’s stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $37.06, for a total transaction of $127,968.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Mary Christina Thomson sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 4th. The stock was sold at an average price of $35.14, for a total transaction of $70,280.00. The disclosure for this sale can be found here. Insiders sold a total of 5,553 shares of company stock valued at $201,957 over the last 90 days. Corporate insiders own 67.68% of the company’s stock.
Shares of SRRA stock opened at $54.52 on Monday. Sierra Oncology has a 1-year low of $14.91 and a 1-year high of $54.97. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -8.05 and a beta of 0.01. The stock’s fifty day simple moving average is $41.30 and its 200-day simple moving average is $30.15.
Sierra Oncology (NASDAQ:SRRA – Get Rating) last issued its quarterly earnings results on Thursday, March 10th. The biotechnology company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.07). On average, analysts anticipate that Sierra Oncology will post -4.88 EPS for the current fiscal year.
About Sierra Oncology (Get Rating)
Sierra Oncology, Inc, a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor.
- Get a free copy of the StockNews.com research report on Sierra Oncology (SRRA)
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.